



Correction to ASX announcement

Brisbane, Australia, 19 August 2022 – ResApp Health Limited (ASX: RAP) (**ResApp**) refers to its previous announcement entitled “Best and Final Confirmation and Bridging Loan” made on 16 August 2022 (**Announcement**) in relation to the proposed acquisition of ResApp by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc., a global biopharmaceutical company) (**Pfizer**) by way of a scheme of arrangement (**Scheme**).

The announcement disclosed the key terms of a loan agreement pursuant to which Pfizer has agreed to provide A\$680,000 to ResApp to enable ResApp to meet its short-term working capital needs during the Scheme period (**Bridging Loan**).

ResApp wishes to correct the description of the Bridging Loan in the Announcement such that the period for remediation of an event of default after receipt of a default notice from Pfizer is in fact 5 business days rather than 10 business days (as was previously disclosed).

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test; SleepCheckRx, a prescription-only smartphone application that screens adults for moderate to severe sleep apnoea; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the Managing Director of ResApp Health.